DefiniGen said it plans to use ERS Genomics' technology to create disease models to support drug discovery for type 2 diabetes and other conditions.
DefiniGen said it plans to use the Broad's technology to create disease models to support the development of therapeutics for metabolic diseases.
Organizers of a data analysis challenge remain hopeful that a recent update to the Connectivity Map resource will lead to breakthroughs in DILI detection by next year.
Using samples from obese women with hepatic steatosis, investigators uncovered ties between the condition, gut microbes, metabolites, and liver gene expression.
Using exomes and linked electronic health records, the team uncovered a loss-of-function variant associated with decreased risk of liver disease and cirrhosis.
Using small RNA sequencing, investigators found miRNAs in the blood that track with cirrhosis, hepatitis, type 2 diabetes, or acetaminophen toxicity.
Called the Glyco Liver Profile, the test uses capillary electrophoresis to measure glycosylation of proteins to diagnosis and monitor chronic liver diseases.
The partners will develop biomarkers and assays to evaluate non-alcoholic steatohepatitis, a disease characterized by liver scarring due to inflammation.
Based on genetic patterns in thousands of individuals with primary sclerosing cholangitis, researchers identified four new risk loci and explored ties to IBD.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.